 This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics the exposure of the trial drug in the body and pharmacodynamics the effect of the investigated drug on the body of rFVIIa activated coagulation factor VII following one single injection of 270 microgkg compared to three injections of 90 microgkg rFVIIa in patients with haemophilia. 